Absence of early platelet increment in healthy mice during decitabine treatment

Treatment of myelodysplastic syndromes includes the administration of the hypomethylating agent decitabine. An early platelet response in decitabine-treated myelodysplastic syndrome patients is a predictor of overall survival. The effect of decitabine on megakaryocytes and the bone marrow, however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Baumann, Juliane, Spindler, Markus, Throm, Yannick, Lübbert, Michael, Bender, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789030/
https://www.ncbi.nlm.nih.gov/pubmed/36564544
http://dx.doi.org/10.1038/s41598-022-26821-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789030/
https://www.ncbi.nlm.nih.gov/pubmed/36564544
http://dx.doi.org/10.1038/s41598-022-26821-8

Ejemplares similares